Estados Unidos · Agencias y tiempo real · PR Newswire

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Publicado por PR Newswire · Estados Unidos hace 4 h

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

También te puede interesar

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

How Dow Jones Is Covering the U.S. Midterms

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Compartir

También te puede interesar

Brazil summons Argentina’s representative after Bolsonaro flees to the US via Argentina

Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape

How Dow Jones Is Covering the U.S. Midterms